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Abstract 
Background: Emerging evidence suggests that the chemokine CXCL12 and its receptor CXCR4, which 
are expressed by glioma stem cells (GSCs), play an important role in tumorigenesis. To provide 
evidence for establishing a new therapy targeting the CXCL12/CXCR4 pathway, we investigated 
whether CXCL12 secreted from GSCs contributed to their proliferation and promoted angiogenesis in 
murine GSCs.  
Methods: Angiogenetic functions and proliferation of GSCs with or without CXCL12 inhibitors were 
evaluated in an in vitro model using tube formation assays, RT-PCR, and proliferation, as well as in an 
in vivo syngenic model.   
Results: In endothelial culture, the morphology and gene expression of GSCs changed from stem cell-
like characteristics to endothelial cell-like features. CXCL12 expression increased in endothelial cell-
like GSCs. CXCL12 blockage with siRNA or shRNA markedly inhibited cell proliferation in vitro. 
CXCL12 knockdown with shRNA also inhibited tumor growth in vivo. On the other hand, 
CXCL12/CXCR4 blockage affected neither tube formation in vitro nor angiogenesis in vivo. 
Conclusions: The CXCL12 secreted from GSCs (autocrine/paracrine CXCL12) regulates their 
proliferation, but probably not angiogenesis. 
 
The final publication is available at link.springer.com 
http://link.springer.com/article/10.1007%2Fs11060-014-1364-y 
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Introduction 
High-grade gliomas are the most common primary brain tumors in adults and include World Health 
Organization (WHO) grade III anaplastic glioma and WHO grade IV glioblastoma multiforme (GBM). 
GBM is an intractable disease, characterized by high proliferation of tumor cells and intense 
angiogenesis. The standard therapy is maximal surgical tumor removal, followed by focal radiotherapy 
and chemotherapy with temozolomide, resulting in a median overall survival not exceeding 2 years [1]. 
Various therapies, including endovascular-targeting therapy and tumor-specific antigen-targeting therapy, 
have been developed for the treatment of patients with high-grade gliomas [2-5]. Glioma stem cells 
(GSCs) express some features that are resistant to chemotherapy and radiation therapy. These cells 
promote tumor angiogenesis by interacting with tumor-associated endothelial cells [6] and by secreting 
high levels of vascular endothelial growth factor (VEGF) [7]. Interestingly, a significant portion of 
endothelial cells in GBM originates from tumor-derived cells [8, 9]. We have studied the molecular 
mechanisms of glioma angiogenesis and glioma-associated endothelial biology using human 
glioblastoma samples [10]. On the other hand, two independent phase III clinical trials for GBM with 
bevacizumab, RTOG-0825, and AVAGlio showed that anti-VEGF therapy in GBM significantly 
prolongs progression-free survival, but does not improve overall survival [11]. These results raise the 
issue of how important anti-angiogenesis therapy is in GBM. 
Chemokines were originally identified as a family of molecules that regulate the chemotaxis of 
leukocytes. In the field of cancer, CXC chemokine ligand 12 (CXCL12/SDF-1) and its receptor, CXCR4, 
also regulate tumorigenesis in breast, lung, prostate, and pancreatic cancers [12-15]. In brain tumors, 
CXCR4 is expressed by a subpopulation of glioblastoma cells with stem cell properties [16]. In contrast, 
the other receptor, CXCR7, is exclusively expressed by the bulk of the more differentiated glioblastoma 
cells as well as most of the established glioblastoma cell lines [17]. A previous study showed that 
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the binding of CXCL12 to CXCR4 induces intracellular signaling through ERK1/2 or PI3K 
[18]. The CXCL12/CXCR4 signaling pathway promotes tumorigenesis of GSCs [16, 19, 20] and 
angiogenesis by inducing VEGF [7]. The function of CXCL12 in GSCs has been analyzed in detail in 
very few reports. One previous report showed that invasive glioma cells significantly overexpress 
CXCR4 and CXCL12 compared to noninvasive glioma cells [21]. 
To better understand the role of CXCL12 in GSC biology, we have now performed an integrated 
study in which we simultaneously evaluated the contribution of the CXCL12/CXCR4 signaling pathway 
to proliferation and angiogenesis using murine GSCs.  
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Materials and Methods  
Cell lines and mice 
A syngenic murine GSC cell line, called the tumor sphere cell line (TS), was established by Dr. 
Hideyuki Saya (Division of Gene Regulation, Keio University School of Medicine, Tokyo, Japan) [22, 
23]. The TS cell was established by overexpressing H-RasV12 in normal neural stem/progenitor cells 
isolated from the subventricular zone of adult mice harboring a homozygous deletion of the Ink4a/Arf 
locus. All mice after TS cell implantation developed highly invasive, hypervascular glioblastoma-like 
tumors, which was green fluorescent protein (GFP)+, nestin+ and CD44+ cell. [23] TS cells were cultured 
in neural stem cell medium (NSM), which consisted of Dulbecco’s modified Eagle medium 
(DMEM)/F12 (Sigma, St. Louis, MO) supplemented with 20 ng/ml epidermal growth factor (PeproTech, 
Rocky Hill, NJ), 20 ng/ml basic fibroblast growth factor (PeproTech), B27 supplement without vitamin 
A (Invitrogen, Carlsbad, CA), 200 ng/ml heparan sulfate, 100 U/ml penicillin, and 100 ng/ml 
streptomycin. The cells were also cultured in endothelial cell medium (ECM), which consisted of 
HuMeda-EG2 (Kurabo, Osaka, Japan) supplemented with 100 U/ml penicillin and 100 ng/ml 
streptomycin. In all experiments, tumor spheres were dissociated to obtain a single-cell suspension 
before use. A syngenic murine glioma cell line, GL261, was obtained from Dr. Masahiro Toda 
(Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan) and maintained in 
Minimal eagle medium (MEM) supplemented with 10% fetal calf serum (FCS) and 1% penicillin-
streptomycin solution (Sigma). The F-2 murine vascular endothelial cell line was derived from a murine 
(BALB/c × C57BL/6) subcutaneous tumor and transformed using ultraviolet radiation. These cells were 
provided by Riken BioResource Center Cell Bank (Tsukuba, Ibaraki) and cultured in DMEM (Gibco®; 
Life Technologies Corp., Carlsbad, CA) with 10% FCS and 1% penicillin-streptomycin. At each 
passage, cells were harvested as single-cell suspensions using trypsin/ethylenediaminetetra-acetic acid. 
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Cells were incubated in a humidified atmosphere containing 5% CO2 at 37°C. 
Male C57BL/6 mice aged 6 weeks were purchased from Clea Japan, Inc. (Tokyo). The mice were 
maintained under constant temperature and humidity in a light-controlled environment with free access 
to food and water. All animal experiments in this study followed the guidelines for animal 
experimentation of the ethics committee of the Laboratory Animal Resource Center in the University of 
Tsukuba. 
 
RNA preparation and RT-PCR 
Total RNA was extracted using RNeasy (QIAGEN, Venlo, Netherlands) according to the 
manufacturer’s protocol. Reverse transcription was performed with 3.68 μg total RNA from each sample 
in a total volume of 20 μl using the PrimeScript II 1st strand cDNA Synthesis Kit (TaKaRa Bio Inc., 
Ohtsu, Shiga, Japan) according to the manufacturer’s protocol. 
The sequences of the forward and reverse primers are as follows: VEGFA-Fw 5′-
TTCAGAGCGGAGAAAGCATT-3′, VEGFA-Rev 5′-GAGGAGGCTCCTTCCTGC-3′, CXCL12-Fw 
5′-GAAGTGGAGCCATAGTAATGCC-3′, CXCL12-Rev 5′-TCCAAGTGGAAAAATACACCG-3′, 
CXCR4-Fw 5′-TTCTCATCCTGGCCTTCATC-3′, CXCR4-Rev 5′-CTTTTCAGCCAGCAGTTTCC-3′, 
CXCR7-Fw 5′-GCCGTACCATTTTGTGGTTC-3′, CXCR7-Rev 5′-TGCAACGCTGTAAAGAGCAC-
3′, β-actin-Fw 5′-GAAGTGTGACGTTGACAT-3′, β-actin-Rev 5′-ACATCTGCTGCTGGAAGGTG-3′. 
β-actin was used as a loading control. PCR was performed using TAKARA Ex Taq (TaKaRa) according 
to the manufacturer’s protocol. The reaction mixture contained 1 µl forward primer (10 µM) and 1 µl 
reverse primer (10 µM) in a final volume of 25 µl. PCR was performed as follows: 94°C for 5 min; 35 
cycles of 94°C for 30 sec, annealing temperature (listed in Table 1) for 90 sec, and 72°C for 60 sec. The 
PCR products were separated on a 2% agarose gel, visualized with ethidium bromide staining, and 
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photographed with FAS-III Series (NIPPON Genetics Co., Ltd., Tokyo, Japan). 
 
Molecular design of gene targets and gene knock down using siRNAs and shRNA 
For siRNA transfection, the designed four pairs of siRNAs (duplexes of sense and anti-sense strands) 
were synthesized by Invitrogen (Valencia, CA). These siRNAs were 25-nucleotide-long double-stranded 
RNA oligos. In our experiments to suppress CXCL12 expression in TS cells, we used the most effective 
siRNAs among them (targeted sequences of CXCL12 were sense 5′-
CCAGAGCCAACGUCAAGCAUCUGAA-3′ and antisense 5′-
UUCAGAUGCUUGACGUUGGCUCUGG-3′). Stealth RNAi negative control with Medium GC 
Duplex (Invitrogen) was used as a negative control. Transient transfection of synthetic siRNA was 
achieved using Lipofectamine 2000 transfection reagent (Invitrogen). In brief, 1 × 105 cells were plated 
in 6-cm culture dishes. Lipofectamine 2000 was diluted in Opti-MEM I medium without serum and 
incubated for 5 min. CXCL12 siRNA or negative control siRNA was each diluted in Opti-MEM I 
medium without serum and added to the diluted Lipofectamine 2000. The mixture was incubated for 20 
min at room temperature to allow the siRNA or negative control siRNA:Lipofectamine 2000 complexes 
to form. A 500-µl aliquot of complexes was added to each dish, and cells were incubated for another 72 
h without replacing the medium. 
For shRNA transfection, the designed shRNAs were synthesized by OriGene (Rockville, MD). The 
targeted sequence of CXCL12 was sense 5′-CCTGCCGGTTCTTCGAGAGCCACATCGCC-3′. An 
ineffective 29-mer scrambled shRNA cassette in the pRS Vector (OriGene) was used as a negative 
control. Transfection was performed the same way as for siRNA. Stable cell lines were prepared in 
medium containing 10 µg/ml puromycin. 
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Quantitative real-time RT-PCR, cell proliferation assays, tube formation assay, and ELISA 
We used the MiniOpticon Real-Time PCR Detection System (Bio-Rad, Hercules, CA) for real-time 
PCR using iQTM SYBR Green Supermix (Bio-Rad). Relative quantification of PCR products was 
calculated after normalization to β-actin. 
For cell proliferation assays, CXCL12 siRNAs or control siRNAs were transfected into TS cells with 
Lipofectamine 2000 (Invitrogen). TS cells were incubated with 2 ml of culture medium ± drug per dish 
at 37°C for 72 h. At the end of the incubation, the cell number was quantified using a hemocytometer 
after staining with crystal violet. 
For the tube formation assay, 1 × 105 cells were incubated in 300 µl growth factor-reduced Matrigel 
(Becton Dickinson and Company, Franklin Lakes, NJ) in a 4-well multi-dish (Thermo Fisher Scientific, 
Waltham, MA) at 37°C in a 5% CO2 incubator. The Matrigel wells were digitized under a 4× objective 
lens (KEYENCE, Osaka, Japan). 
For ELISA, TS cells were plated at 1.25 × 106 cells/ml, cell culture supernatants were collected after 
24 h of culture, and VEGF concentrations were measured using Quantikine ELISA Kits (R&D Systems, 
Minneapolis, MN). All standards and samples were assayed in duplicate. All assays were performed 
according to the protocols recommended by the manufacturers. 
 
Injection of TS cells into C57BL/6 Mice 
As a subcutaneous tumor mouse model, TS cells transfected with control shRNA or CXCL12 shRNA 
were injected subcutaneously (1 × 105 cells/100 μl) into the back area of C57BL/6 mice, and tumor 
burden was observed for up to 4 weeks. The size of the tumors was measured three times per week with 
calipers. Tumor volume (TV) was calculated using the formula: TV = W2*L/2 (where W is the shortest 
diameter, and L is the longest diameter). Four weeks after implantation, mice were sacrificed by cervical 
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spine dislocation under anesthesia. 
As an intracranial tumor mouse model, C57BL/6 mice were placed in a stereotactic frame (SR-5M with 
IMS-3 microinjector; Narishige, Tokyo, Japan) under anesthesia with isoflurane (induction 4%; 
maintenance 2%). The striatum was targeted unilaterally in the right hemisphere using a 27-G needle 
(Hamilton) connected to a Hamilton 100-μl syringe. The stereotactic coordinates for the microinjections 
were: 0.5 mm anterior, 2.5 mm lateral to bregma. TS cells transfected with control shRNA or CXCL12 
shRNA were injected intracranially (1 × 105 cells/10 µl) over a period of 3 min. Mice were sacrificed 
after 2 weeks. 
 
Histological analysis including Immunohistochemistry (IHC) 
For IHC, frozen tumor tissue samples were fixed with zinc fixative for 24 h, embedded in OTC 
compound, and cut into 5-µm sections with a cryostat. After washing the slides twice in distilled water, 
they were incubated with rabbit polyclonal anti-CXCL12 antibodies (Santa Cruz Biotechnology, Inc., 
Dallas, TX; 1:50), rabbit monoclonal anti-von willebrand factor (vWF) antibodies (Dako Denmark A/S, 
Glostrup, Denmark; 1:200), or rat monoclonal anti-F4/80 antibodies (AbD Serotec, Oxford, UK; 1:100) 
for 1 h at room temperature. Subsequently, sections were rinsed twice with phosphate-buffered saline 
(PBS) and incubated with anti-rabbit Alexa Fluor 555 antibody (Life Technologies Corp.) or anti-rat 
Alexa Fluor 594 antibody (Life Technologies Corp.) for 30 min at room temperature followed by 
washing with PBS for 10 min. The sections were then incubated in DAPI for 2 min followed by washing 
with PBS for 5 min. The positive area (pixels/view) was measured using morphometry software 
(KEYENCE).  
Prior to CD31 staining, sections were incubated with 0.3% hydrogen peroxide in methanol for 20 min 
to inhibit endogenous peroxidases. Sections were incubated with rat monoclonal anti-CD31 antibodies 
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(Becton Dickinson and Company; 1:10) for 1 h at room temperature. Binding of the primary antibodies 
was detected using anti-rat biotinylated antibody (Dako) and the LSAB 2 streptavidin–biotin horseradish 
peroxidase kit (Dako). Antibody complexes were then visualized by incubation with diaminobenzidine 
chromogen (Lab Vision kit). Sections were counterstained with Mayer’s hematoxylin. 
 
Statistical analysis 
The data are presented as the mean ± standard error. Statistically significant differences between the 
groups were determined with the Student’s two-tailed t-test and/or Tukey’s honestly significant 
difference (HSD) test. All p-values were 2-sided; values were considered statistically significant at p < 
0.05. 
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Results 
The morphology and gene expression of TS cells changed from stem cell-like to endothelial cell-
like in endothelial cell medium 
Previously, we demonstrated that glioma-derived endothelial cells are genetically and functionally 
distinct from normal endothelial cells [10]. In addition, a subpopulation of GSCs is able to differentiate 
into functional endothelial cells [8, 9]. Thus, to examine the angiogenic potential of TS cells in vitro, we 
analyzed the molecular, morphological, and expression changes in NSM or ECM. TS cells formed 
floating neurospheres in NSM, whereas the cells changed to adherent cells in ECM. TS cells in NSM did 
not form tube-like structures on Matrigel. After pre-incubation for 10 days in ECM, TS cells formed 
tube-like structures on Matrigel. In contrast, GL261 cells did not form tube-like structures regardless of 
pre-incubation (Figure 1A, B). TS cells in ECM consisted of adherent and floating cells. We analyzed 
each type of TS cells separately. Only the adherent type formed tube-like structures (Figure 1C). Thus, 
adherent GSCs in ECM acquired the ability to form tube-like structures.  
To analyze the molecular biological effects due to differences in culture conditions, we performed 
RT-PCR for endothelial cell-associated molecules. VEGF and CXCL12 expression in TS cells in ECM 
was higher than expression in TS cells in NSM. CXCR4 was expressed only in TS cells, and the 
expression was not affected by the type of medium (Figure 2A). When we separately analyzed 
expression in the adhesive type and the floating type of cells in ECM, the adherent cells expressed 
higher levels of VEGF and CXCL12 than the floating cells (Figure 2B). The adhesive TS cells acquired 
CXCL12 expression at the same time as the tube-like morphological change in ECM. 
 
CXCL12 regulates the proliferation of GSCs in vitro 
To evaluate the functional role of CXCL12 activity in TS cells, we used AMD3100 (CXCR4 
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antagonist) for inhibition of proliferation. Treatment with AMD3100 significantly reduced proliferation 
in a concentration-dependent manner (Figure 3A). For direct evidence of the importance of CXCL12 
secreted from GSCs, CXCL12 siRNA was used to silence endogenous CXCL12 mRNA. CXCL12 
siRNA efficiently reduced CXCL12 mRNA expression in TS cells, and transfection of the siRNA into 
TS cells resulted in 63% inhibition of the cell proliferation compared to control siRNA transfection 
(Figure 3B). We next performed CXCL12 shRNA knockdown using another sequence of CXCL12. 
Cells were transfected with lipofectamine and CXCL12 shRNA or control shRNA, and stable cell lines 
were established using puromycin selection. Similar to the CXCL12 siRNA knockdown results, we 
observed that CXCL12 shRNA in TS cells significantly reduced CXCL12 mRNA expression and 
attenuated cell growth in vitro (Figure 3C). 
 
CXCL12/CXCR4 inhibitors do not affect formation of tube-like structures 
To evaluate whether formation of the tube-like structures depends on CXCL12/CXCR4 signaling, 
AMD3100 or CXCL12 shRNA in TS cells was used in the tube formation assay. Inhibition of 
CXCL12/CXCR4 did not affect tube formation (Figure 4A).  Figure 4B shows that VEGF production 
was up-regulated by fetal bovine serum but was not affected by CXCL12 and AMD3100. These in vitro 
data indicate that the functions of TS cells that are related to angiogenesis were independent of 
CXCL12/CXCR4 signaling. 
 
CXCL12 silencing directly inhibits tumor growth in an in vivo model 
We investigated the growth properties of GSCs in vivo after autocrine CXCL12 knockdown. 
Subcutaneous transplantation models of TS cells transfected with control shRNA or CXCL12 shRNA 
were used. Quantification of tumor size showed that CXCL12 knockdown in TS cells resulted in 
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significantly smaller tumors than control cells (Figure 5A). CXCL12 expression in glioma tissues from 
TS cells was observed using IHC. TS cells with CXCL12 shRNA tended to be lower than that from TS 
cells with control shRNA (Figure 5B). To determine whether the inhibition effect was associated with 
angiogenesis in the glioma tissue, the numbers of vessels in the glioma tissues obtained from intracranial 
TS cell transplantation and subcutaneous transplantation were calculated. As shown in Figure 5C, IHC 
using a vWF antibody and CD31 antibody showed that TS cells led to development of tumor vessels 
regardless of CXCL12 shRNA both in the subcutaneous and intracranial tumor models, suggesting that 
CXCL12 silencing directly inhibited glioma growth independent of angiogenesis.  
GFP+ cells (TS cells) were included among the CD31+ endothelial cells (Figure 5D), demonstrating 
TS cells were differentiated into endothelial cells. We did not detect a difference in angiogenesis 
regardless of CXCL12 reduction. To analyze the reason, we performed IHC with anti-F4/80 antibody to 
label macrophages/ microglias, which typically promote angiogenesis. We found that many F4/80+ cells 
had infiltrated into the tumor, regardless of CXCL12 (Figure 5E).  
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Discussion 
Previous studies have not clarified whether CXCL12/CXCR4 signal blockage inhibits GSC growth as 
a direct effect of the signal blockage or as an indirect effect through blocking angiogenesis. In addition, 
the importance of another effect due to differentiation of GSCs into endothelial cells should be 
considered. Thus, we assessed the direct and indirect effects. 
First, regarding the direct effect of CXCL12 on the GSCs themselves, we hypothesized that CXCL12 
secreted from GSCs would induce cell proliferation through CXCR4 activation. In the present study, we 
showed that CXCL12 blockage inhibited tumor growth using murine GSCs both in vitro and in vivo. In 
addition, GSCs expressed CXCL12 mRNA (Figure 2 and 3) and CXCL12 protein (Figure5B). A 
previous paper showed that CXCL12 and CXCR4 associate to enhance proliferation and migration of 
glioma cells [24]. 
Our data showed that endothelial-like differentiation of GSCs was associated with CXCL12 
expression (Figure1 and 2). Our previous experiments have shown that glioblastoma-derived endothelial 
cells exhibit a phenotype of activated endothelial cells, as reflected in the high expression of VEGF, 
CXCL12, and CXCR7 [10]. Another previous study reported that endothelial cells interact closely with 
brain cancer stem cells and that their interactions accelerate initiation and tumor growth to maintain 
perivascular stem cell niches [25]. Because GSC recruitment to the perivascular niche depends on the 
CXCL12/CXCR4 pathway, we propose that high CXCL12 expression by endothelial-like GSCs 
enhances the interaction between GSCs and tumor vessels. Recent animal studies have suggested that 
CXCL12 mediates apoptosis resistance to chemotherapy in glioma cells [26, 27]. These results indicate 
that CXCL12 provided by endothelial-like GSCs may be an important target for therapeutic approaches. 
The role of endothelial-like GSCs may be to create a particular environment for GSCs rather than to 
directly facilitate growth. 
 
 
14 
 
Second, regarding the indirect effect of host-derived endothelial cells, another study reported that 
CXCR4 promotes GSC-mediated VEGF production and tumor angiogenesis [7]. Several studies have 
reported that GSCs promote angiogenesis via VEGF [28, 29]. VEGF is an important molecule in tumor 
vessel formation, and VEGF neutralizing antibodies block tube formation [30]. However, CXCL12 did 
not alter VEGF production in our study (Figure 4B). CXCL12/CXCR4 signal blockage in GSCs 
significantly inhibited tumor growth without affecting angiogenesis (Figure 4A, 5A, C). We cannot 
explain this discrepancy between our study using a murine syngenic model and the result from another 
study regarding CXCR4 promotion and VEGF production using primary human tumor-derived 
xenograft models [7]. Therefore, further studies will be needed using other GSC models. 
Considering our results, GSCs may activate angiogenesis independent of CXCL12/CXCR4 signaling. 
A possibility is that GSCs may increase the accumulation of host macrophages/microglias and 
endothelial progenitor cells independent of CXCL12/CXCR4 signaling. Indeed, we performed a 
preliminary analysis of the infiltration of macrophages/microglias in GSC tissues with IHC using anti-
mouse F4/80 antibody. Regardless of CXCL12 knockdown, many macrophages/microglias infiltrated 
into GSCs tissues (Figure 5E). These cells may secrete large amount of VEGF and other molecules in 
tumor tissue. Further studies will be needed to access the reason of the accumulation of host 
macrophages/microglias. And a further limitation, our study did not assess the interactions between 
CXCL12/CXCR4 signaling and cell-cycle/cell-death-related molecules or other regulatory proteins 
including ubiquitin, which is also a natural ligand of CXCR4 [31]. Such evaluations using our model 
should be planned in the future.. 
In conclusion, CXCL12 blockage markedly inhibited GSC growth in vitro and in vivo. These results 
indicate that CXCL12 secreted from GSCs is a key system for glioma tumorigenesis. In contrast, the 
effect of CXCL12 blockage against angiogenesis is limited.  
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Fig. 1 In vitro culture of TS cells in endothelial conditions indicating functional features similar to endothelial cells. 
A. Endothelial tube formation ability of TS cells and GL261 GBM cells. Tube formation was performed after pre-incubation 
for 10 days in neural stem cell medium (NSM), Minimal eagle medium (MEM), or endothelial cell medium (ECM). B. Mean 
tube lengths in the four groups (n = 3 per group) were assessed by counting four fields. *p < 0.01 compared to other cells 
(Tukey’s HSD test). C. Endothelial tube formation ability by adherent TS cells and floating TS cells in ECM. Adherent-type 
TS cells formed tubes. 
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Fig. 2 In vitro culture of TS cells in endothelial conditions induces molecular features similar to endothelial cells. 
A. The mRNA expression of VEGF, CXCL12, CXCR4, CXCR7, and β-actin in F-2 endothelial cells, GL261 GBM cells, and 
TS cells. TS cells were analyzed in neural stem cell medium (NSM) and endothelial cell medium (ECM). B. The mRNA 
expression of CXCL12 and β-actin in adherent TS cells and floating TS cells in ECM. 
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Fig. 3 The effect of blocking CXCL12/CXCR4 signaling on TS cell proliferation. 
A. TS cell proliferation was examined when CXCL12/CXCR4 signaling was blocked using the CXCR4 antagonist, 
AMD3100. *p < 0.05, **p < 0.01, Tukey’s HSD test. B. Left: Real-time RT-PCR analysis of the effect of siRNA targeting of 
CXCL12 on TS cells. Expression of CXCL12 mRNA was measured with quantitative real-time PCR and normalized to β-
actin mRNA expression. Right: The effects of blocking CXCL12 signaling using CXCL12 siRNA in vitro. CXCL12 siRNA 
or control siRNA was transfected into 1 × 105 TS cells with Lipofectamine 2000. *p < 0.01 (Student’s t-test). C. Left: Real-
time RT-PCR analysis of the effect of shRNA targeting of CXCL12 in TS cells. Expression of CXCL12 mRNA was 
measured with quantitative real-time PCR and normalized to β-actin mRNA expression. Right: The effects of blocking 
CXCL12 signaling using CXCL12 shRNA in vitro. *p < 0.01 (Student’s t-test). 
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Fig. 4 Role of the CXCL12/CXCR4 pathway in endothelial cell-like changes. 
A. Endothelial tube formation ability of TS cells. Tube formation was performed after pre-incubation in ECM for 10 days. 
AMD3100 was used at 10 μM during the pre-incubation. B. VEGF production by stimulated TS cells in culture medium. 
VEGF production (protein concentration; pg/ml) was determined with supernatants from TS cell cultures using ELISA. FBS 
was used at 2%; CXCL12 was used at 100 ng/ml; AMD3100 was used at 10 μM. Protein data are expressed as mean ± SEM. 
*p < 0.01, significant VEGF secretion was observed only in FBS treatment group, when compared to each other group 
(Tukey's HSD test).  
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Fig. 5 Effect of blocking CXCL12 signaling in TS cells on tumor growth and angiogenesis. 
A. The effect of blocking CXCL12/CXCR4 signaling using CXCL12 shRNA in an in vivo subcutaneous TS cell 
transplantation model. *p < 0.05 (Student’s t-test). B-E. Immunohistochemical (IHC) analysis of CXCL12 (B), vWF (C), 
CD31 (C, D), and F4/80 (E). Comparison of positive areas in tumor tissue regions obtained from the TS cell transplantation 
model using IHC staining (intracranial tumor tissues obtained 2 weeks after implantation: control, n = 3, shRNA, n = 3; 
subcutaneous tumor tissues obtained 4.5 weeks after implantation: control, n = 3, shRNA, n = 5). Mean positive areas in the 
two groups were assessed by counting high-power fields with the most intense tumor site. CXCL12 is expressed in glioma 
tissues from TS cells. n.s. = not significant. Double staining for CD31 (red) and GFP (green) in the intracranial TS cell 
transplantation model (D, arrowhead, double-positive cell; arrow, CD31 single-positive cell).  
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